Mostrar el registro sencillo del ítem

Effect of mirtazapine on craving in cocaine-dependent patients

dc.creatorNanni-Alvarado, Ricardoes_ES
dc.creatorGonzalez, Marioes_ES
dc.creatorLima, Carloses_ES
dc.creatorMarín-Navarrete, Rodrigoes_ES
dc.creatorBarbosa-Méndez, Susanaes_ES
dc.creatorSalazar-Juárez, Albertoes_ES
dc.date2021
dc.date.accessioned2024-05-09T18:22:23Z
dc.date.available2024-05-09T18:22:23Z
dc.date.issued2022
dc.identifierOE09IC21es_ES
dc.identifier.issn1557-1874
dc.identifier.issn1557-1874
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/7966
dc.identifier.urihttps://doi.org/10.1007/s11469-021-00547-6
dc.descriptionDrug craving is the intense desire to consume drugs of abuse that promote compulsive drug use and cause drug relapse, following long-term drug withdrawal. Antidepressants like mirtazapine could be a real alternative therapy to attenuate or prevent cocaine withdrawal symptoms and drug craving. In the present study, we examined the efficacy of mirtazapine on cocaine craving in cocaine-detoxified patients during its maintenance phase. A two-arm randomized, placebo-controlled, double-blind clinical trial was scheduled for a complete 12-week period. A total of 64 cocaine-dependent individuals were randomly allocated into two groups: the placebo group (n = 32) and the mirtazapine (n = 32) groups. Both Cocaine Craving Questionnaire (CCQ-G) and the Symptom Check List 90 (SCL-90-R) were used to assess cocaine craving and the psychopathological status of patients, respectively. Assessments were performed once a week for 12 weeks during the study. Mirtazapine (30 mg/kg) was given daily during the 12 weeks of enduring drug withdrawal. A daily dosing regimen of mirtazapine (30 mg/kg) for 12 weeks significantly decrease the cocaine craving, cocaine use, and some psychiatric symptoms which included depression, anxiety, and mood-negative states along the 12 weeks that endured the study. These data suggest that mirtazapine given to cocaine-dependent patients for 12 weeks of drug withdrawal significantly decreases and controls cocaine-craving behavioral alterations. Furthermore, the present study demonstrates that mirtazapine reduces efficiently some co-morbid psychiatric symptoms that appear during cocaine withdrawal. These results argue in favor of using mirtazapine for treating cocaine addiction, reducing comorbid cocaine-withdrawal symptomology, and relieving drug craving in addicted subjects. Clinical trial number: NCT ID: NCT01949571.es_ES
dc.formatPDFes_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.relation20:2770-2786
dc.rightsAcceso Cerradoes_ES
dc.titleEffect of mirtazapine on craving in cocaine-dependent patientses_ES
dc.typeArticuloes_ES
dc.contributor.affiliationClinic of Addictive Disorders, National Institute of Psychiatry, Ramón of the Fuente Muñiz, Mexico City, Mexico
dc.contributor.emailazazel_vamp@yahoo.com.mx (Alberto Salazar-Juárez)
dc.relation.jnabreviadoINT J MENT HEALTH ADDICT
dc.relation.journalInternational Journal of Mental Health and Addiction
dc.identifier.placeEstados Unidos
dc.date.published2022
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
dc.identifier.eissn1557-1882
dc.identifier.eissn1557-1882
dc.identifier.doi10.1007/s11469-021-00547-6
dc.subject.kwMirtazapine
dc.subject.kwCocaine
dc.subject.kwPharmacotherapy
dc.subject.kwCraving


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem